T. C. Chou, Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies, Pharmacological Reviews, vol.58, issue.3, pp.621-681, 2006.

R. Bayat-mokhtari, Combination therapy in combating cancer, Oncotarget, vol.8, issue.23, pp.38022-38043, 2017.

H. Zahreddine and K. L. Borden, Mechanisms and insights into drug resistance in cancer, Frontiers in Pharmacology, vol.4, p.28, 2013.

T. P. Martin, D. Baguley, ;. Re, and . Snapp, Postoperative validation of bone-anchored implants in the single-sided deafness population, Otology & Neurotology, vol.34, issue.4, p.777, 2012.

B. Choi, Sensitization of lung cancer cells by altered dimerization of HSP27, Oncotarget, vol.8, issue.62, pp.105372-105382, 2017.

L. M. Weiner, R. Surana, and S. Wang, Monoclonal antibodies: versatile platforms for cancer immunotherapy, Nature Reviews Immunology, vol.10, issue.5, pp.317-327, 2010.

J. D. Mellor, M. P. Brown, H. R. Irving, J. R. Zalcberg, and A. Dobrovic, A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer, Journal of Hematology & Oncology, vol.6, p.1, 2013.

A. Kowalczyk, The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells, Cancer Letters, vol.281, issue.2, pp.171-182, 2009.

M. W. Retter, Characterization of a proapoptotic antiganglioside GM2 monoclonal antibody and evaluation of its therapeutic effect on melanoma and small cell lung carcinoma xenografts, Cancer Research, vol.65, issue.14, pp.6425-6434, 2005.

K. Nakamura, Apoptosis induction of human lung cancer cell line in multicellular heterospheroids with humanized antiganglioside GM2 monoclonal antibody, Cancer Research, vol.59, issue.20, pp.5323-5330, 1999.

D. Cochonneau, Cell cycle arrest and apoptosis induced by O-acetyl-GD2-specific monoclonal antibody 8B6 inhibits tumor growth in vitro and in vivo, Cancer Letters, vol.333, issue.2, pp.194-204, 2013.

T. C. Chou and N. Martin, CompuSyn for drug combinations: PC software and user's guide: a computer program for quantitation of synergism and antagonism in drug combinations, and the determination of IC 50 and ED 50 and LD 50 values, 2005.

N. Alvarez-rueda, A monoclonal antibody to O-acetyl-GD2 ganglioside and not to GD2 shows potent anti-tumor activity without peripheral nervous system cross-reactivity, PLoS One, vol.6, issue.9, p.25220, 2011.

S. Faraj, Neuroblastoma chemotherapy can be augmented by immunotargeting O-acetyl-GD2 tumor-associated ganglioside, Oncoimmunology, vol.7, issue.1, p.1373232, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01596068

F. Ishikawa, Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice, Blood, vol.106, issue.5, pp.1565-1573, 2005.

M. H. Ullman-cullere and C. J. Foltz, Body condition scoring: a rapid and accurate method for assessing health status in mice, Laboratory Animal Science, vol.49, issue.3, pp.319-323, 1999.

B. A. Teicher, Assays for in vitro and in vivo synergy, Methods in Molecular Medicine, vol.85, pp.297-321, 2003.

D. B. White, H. K. Slocum, Y. Brun, C. Wrzosek, and W. R. Greco, A new nonlinear mixture response surface paradigm for the study of synergism: a three drug example, Current Drug Metabolism, vol.4, issue.5, pp.399-409, 2003.

T. Mosmann, Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays, Journal of Immunological Methods, vol.65, issue.1-2, pp.55-63, 1983.

L. Huyck, C. Ampe, and M. Van-troys, The XTT cell proliferation assay applied to cell layers embedded in three-dimensional matrix. Assay and Drug Development Technologies, vol.10, pp.382-392, 2012.

J. Thompson, Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts, Clinical Cancer Research, vol.5, issue.11, pp.3617-3631, 1999.

M. Tan, H. B. Fang, G. L. Tian, and P. J. Houghton, Experimental design and sample size determination for testing synergism in drug combination studies based on uniform measures, Statistic in Medicine, vol.22, issue.13, pp.2091-2100, 2003.

X. X. Tang, Implications of EPHB6, EFNB2, and EFNB3 expressions in human neuroblastoma. Proceding of the National Academy of Sciences of the United States of America, vol.97, pp.10936-10941, 2000.

R. R. Mehta, J. M. Graves, G. D. Hart, A. Shilkaitis, and T. K. Das-gupta, Growth and metastasis of human breast carcinomas with Matrigel in athymic mice, Breast Cancer Research and Treatment, vol.25, issue.1, pp.65-71, 1993.

P. Mullen, A. Ritchie, S. P. Langdon, and W. R. Miller, Effect of Matrigel on the tumorigenicity of human breast and ovarian carcinoma cell lines, International Journal of Cancer, vol.67, issue.6, pp.816-820, 1996.

C. Feng, S. Tang, J. Wang, Y. Liu, and G. Yang, Topotecan plus cyclophosphamide as maintenance chemotherapy for children with high-risk neuroblastoma in complete remission: short-term curative effects and toxicity. Nan Fang Yi Ke Da Xue Xue Bao, vol.33, pp.1107-1110, 2013.

N. K. Cheung, Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma, Journal of Clininical Oncology, vol.5, issue.9, pp.1430-1440, 1987.

A. B. Nair and S. Jacob, A simple practice guide for dose conversion between animals and human, Journal of Basic Clinical Pharmacy, vol.7, issue.2, pp.27-31, 2016.

D. Dayde, Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20, Blood, vol.113, issue.16, pp.3765-3772, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00616466

W. J. Racki, NOD-scid IL2rgamma(null) mouse model of human skin transplantation and allograft rejection, Transplantation, vol.89, issue.5, pp.527-536, 2010.